

Micafungin:

Class: Antifungal Agent.

Indications:

Treatment of esophageal candidiasis; *Candida* prophylaxis in patients undergoing hematopoietic stem cell transplant (HSCT); treatment of candidemia, acute disseminated candidiasis, and other *Candida* infections (peritonitis and abscesses).

Available dosage form in the hospital: 50MG INJ.

Dosage:

Candidemia, acute disseminated candidiasis, and *Candida* peritonitis and abscesses: I.V.: 100 mg once daily; mean duration of therapy (from clinical trials) was 15 days (range: 10-47 days)

Esophageal candidiasis: I.V.: 150 mg once daily; mean duration of therapy (from clinical trials) was 15 days (range: 10-30 days)

Prophylaxis of *Candida* infection in hematopoietic stem cell transplantation: I.V.: 50 mg once daily; mean duration of therapy (from clinical trials) was 19 days (range: 6-51 days)

Dosing: Renal Impairment : No dosage adjustment necessary.

Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on

intermittent hemodialysis.

Common side effect:

Central nervous system: Fever , headache , dizziness .

Endocrine & metabolic: Hypokalemia , hypomagnesemia .

Gastrointestinal: Diarrhea , nausea , vomiting .

Hematologic: Thrombocytopenia , neutropenia .

Dermatologic: Rash ,pruritus .

Pregnancy Risk Factor: C